Gilead (GILD) stock in focus as its HIV anti-viral lenacapavir shows promise in HIV prevention with once-yearly PrEP ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

After Gilead’s lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has ...

Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.

Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...

Gilead said two experimental once-a-year versions of its HIV prevention shot lenacapavir passed muster in an early-stage ...

In 2024, technology stocks involved in artificial intelligence (AI) led the Nasdaq-100 index higher, while healthcare stocks ...

Bill Strazzullo, Bell Curve Trading chief market strategist, said in a latest program on CNBC that the market rally that ...

NanoViricides, Inc. (the “Company”)(NYSE American:NNVC), a clinical-stage global leader developing revolutionary broad-spectrum antiviral drugs that the viruses cannot escape, declared today that its ...

The Conference on Retroviruses and Opportunistic Infections 2025 opened with a session dedicated to informing attendees about ...